 NEW YORK, June 11, 2021 GLOBE NEWSWIRE -- TG Therapeutics, Inc. NASDAQ: TGTX, today announced data from TG-1701, the Companys investigational once-daily, oral BTK inhibitor, as a monotherapy and as a triple therapy in combination with ublituximab, the Companys novel glycoengineered anti-CD20 monoclonal antibody, and UKONIQ umbralisib, the Companys once-daily, inhibitor of PI3K-delta and CK1-epsilon in patients with front line or relapsedrefractory non-Hodgkins lymphoma NHL and chronic lymphocytic leukemia CLL. Data from this trial were made available on demand this morning during the 3032 European Hematology Association EHA Virtual Congress. The data presented today were previously presented at the American Society of Clinical Oncology ASCO annual meeting. 